PPARG and ischemic stroke: With the exception of ischemic stroke, for which several large trials have reported promising outcomes with pioglitazone and rosiglitazone [1,99], the results from clinical trials for PPARγ agonists in CNS disease have not typically lived up to the promising preclinical data.